Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine explains how insights from the Oncology Care Index are helping address oncologists’ challenges with keeping up amid a surge in cancer treatment breakthroughs.
Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a washout period or loading dose in patients with hemophilia A.
Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the development of innovative cancer therapies.
Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% compared to on-demand treatment with bypassing agents in patients with hemophilia A or B.
The label update for Amyvid adds guidance for assessing amyloid plaque levels and may help inform diagnostic and treatment decisions in patients being evaluated for Alzheimer disease.
Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% response rates in rare neuroendocrine tumors, offering a potential advance over traditional chemotherapy.
Under the renewed deal, Bayer and Tsinghua University will work to enhance the drug discovery and development process across key therapeutic areas, with Bayer continuing to provide funding and scientific support.
Final results from the Phase IV PEARL trial show that 66% of patients treated with Ajovy for episodic migraine and more than half of those treated for chronic migraine who responded during the first six months maintained a ≥50% reduction in monthly migraine days.
Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming responsibility for global development and commercialization if it exercises its option.
Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant improvements in both progression-free survival and objective response rate in patients with relapsed or refractory large B-cell lymphoma.
Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a pipeline-in-a-molecule.
Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with hemophilia A without factor VIII inhibitors.
Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong overall response rate and duration of response in patients with previously treated, locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
The drug-maker cited concerns over deceptive marketing and the selling of compounded GLP-1 medications.
Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data presented at ASCO 2025.
Results from the Phase III QWINT-1, QWINT-3, and QWINT-4 trials show that once-weekly insulin efsitora alfa achieved A1C reductions up to 1.31%, demonstrating non-inferiority to daily basal insulin in patients with type 2 diabetes.
Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults with overweight or obesity and a weight-related medical condition, but without diabetes.
The Acuvue Oasys Max 1-Day Multifocal marks the first and only daily disposable contact lens to be available for people with both astigmatism and presbyopia.
This is the latest partnership for PharmaJet.
Members will have access to oncology specialists.
Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in patients treated with Monjuvi combined with rituximab and lenalidomide for relapsed or refractory follicular lymphoma.
During a high-level US visit, the Department of Health—Abu Dhabi signed strategic agreements with Abbott, Boehringer Ingelheim, and Sanofi to boost pharmaceutical manufacturing, expand vaccine development, and advance digital health and clinical research.
The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated favorable trends towards slowed motor decline in patients with early-stage Parkinson disease.
Dupixent is the first and only targeted therapy to receive FDA approval for bullous pemphigoid.
Harliku becomes the first FDA-approved treatment for alkaptonuria, indicated to reduce homogentisic acid levels in affected adults.
Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 trials, which show that ≥99.9% of patients treated with Yeztugo remained HIV-negative.
The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced gadolinium dose, supporting safer repeat use in adults and pediatric patients.
Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.
Johnson & Johnson submitted a supplemental Biologics License Application to expand Stelara’s use to children aged two years and older with Crohn disease, supported by data from the Phase III UNITI-Jr trial.
Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer treatment discontinuations due to adverse events compared to topiramate for preventative migraine treatment.
